CLAIMS

1. Use of an inhibitory agent in the manufacture of a medicament for the treatment of cancer, wherein the inhibitory agent is an anti-LIF antibody, and wherein the cancer comprises non-small cell lung cancer.

2. Use of an inhibitory agent in the manufacture of a medicament for the treatment of cancer, wherein the inhibitory agent is an anti-LIF antibody, and wherein the cancer comprises pancreatic cancer.

3. The use according to claim 1 or 2, wherein the cancer is characterized by presenting a concentration of LIF which is at least 5% greater than that occurring in a control sample.

4. The use according to claim 1 or 2, wherein said cancer is caused by a high activity of the JAK-STAT signaling pathway.

5. The use according to any of claims 1 to 4, wherein the medicament comprises a pharmaceutical composition comprising a therapeutically effective amount of the inhibitory agent together with a pharmaceutically acceptable carrier.